[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521772":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":46,"collaborators":7,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":7,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","NHWD-870","The base dosage administered is 2.0 mg\u002Fdose\u002Fday, and the frequency and dose of administration may be adjusted based on safety data.",[14,20],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Yongchang Zhang, MD","CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":21,"role":16,"phone":17,"phoneExt":7,"email":22},"Nong Yang","yangnong0217@163.com",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Hunan Provincal Tumor Hospital","RECRUITING","Changsha","Hunan","410013","China","CN",{"type":33,"coordinates":34},"Point",[35,36],112.97087,28.19874,{"lat":36,"lon":35},[39,42,44],{"name":40,"role":16,"phone":41,"phoneExt":7,"email":22},"Nong Yang, MD","+86 731 89762323",{"name":15,"role":16,"phone":43,"phoneExt":7,"email":19},"+86 731 89762327",{"name":40,"role":45,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Yongchang Zhang","Professor, Deputy Director of Thoracic Oncology Department","100521772","compassionate-use-study-of-nhwd-870-in-patients-with-advanced-solid-tumors-or-lymphomas-carrying-nut-rearrangement-100521772",false,"NCT06073938","Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","A Real-World Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement","Inclusion Criteria:\n\n1. Signing an informed consent form;\n2. Patients with advanced solid tumors or lymphomas definitively diagnosed by pathology;\n3. Age ≥18 and ≤75 years;\n4. Eastern Cooperative Oncology Group (ECOG) score physical status score of 0 to 1;\n5. Expected survival of \\>3 months;\n6. NUT positive confirmed by molecular testing.\n\nExclusion Criteria:\n\nSubjects who meet one or more of the following criteria will be excluded:\n\n1. Other serious complications (such as uncontrolled infection, myocardial infarction within 6 months, high blood pressure (≥ 160\u002F100mmHg) and thromboembolic disease that cannot be controlled by drug intervention, etc.);\n2. The adverse reactions of previous anti-tumor therapy have not been restored to CTCAE 5.0 ≤ Grade1 (except for hair loss, anemia and other toxicities judged by researchers to be unsafe);\n3. History of substance abuse;\n4. Inability to take drugs due to dysphagia (except for patients who receive nutrients through a gastric tube due to dysphagia), or conditions that the investigator determines seriously affect gastrointestinal absorption;\n5. Patients with a history of other serious systemic diseases who are judged by the investigator to be unsuitable for participating in clinical trials;\n6. Alcoholics or those who drink more than 28 units of alcohol per week (1 unit = 285 mL of beer or 25 mL of spirits or 1 glass of wine);\n7. Suffering from uncontrollable mental illness;\n8. Pregnant or lactating women, or patients of childbearing age (including male subjects) with pregnancy plans;\n9. Active hepatitis B (viral titer \\>103), hepatitis C or HIV ( );\n10. Long-term treatment with high-dose corticosteroids or other immunosuppressants, such as those who have undergone organ transplantation, or those who have received systemic glucocorticoids (such as prednisone\\> 10 mg\u002Fday or equivalent drugs) or other immunosuppressant therapy within 14 days before the first use of the study drug; Exceptions are given for topical, ocular, intra-articular, intranasal and inhaled corticosteroid therapy; short-term use of glucocorticoids for prophylaxis (e.g., prevention of contrast allergy);\n11. The investigator believes that the subject is not suitable to participate in this clinical study for other objective reasons.","ALL","18 Years","75 Years",{"count":60,"type":61},30,"ESTIMATED","OBSERVATIONAL","The NHWD-870 Phase I clinical trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced tumors. The objectives of this retrospective study were to preliminarily evaluate the anti-tumor efficacy of NHWD-870 HCl in patients with advanced solid tumors or lymphomas and to preliminarily evaluate biomarkers associated with the efficacy of NHWD-870 HCl in the treatment of patients with advanced solid tumors or lymphomas, to provide a basis for identifying the enriched population for the late-stage trial.",[65],"Advanced Solid Tumors or Lymphomas","2024-09-17",{"date":68,"type":69},"2024-09-19","ACTUAL",{"date":71,"type":69},"2022-09-20",{"date":73,"type":61},"2025-06-30",{"name":5,"class":6},1]